Journal of Food Technology and Preservation

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +44-1518-081136

Perspective - Journal of Food Technology and Preservation (2024) Volume 8, Issue 5

Exploring Therapeutic Strategies for COVID-19 Management

Ngozi Eze *

Department of Industrial Microbiology , University of Lagos, Nigeria

*Corresponding Author:
Ngozi Eze
Department of Industrial Microbiology , University of Lagos, Nigeria
E-mail: Eze45@unilag.edu.ng

Received: 27-Aug-2024, Manuscript No. AAFTP-24-146237 ; Editor assigned: 29-Aug-2024, PreQC No. AAFTP-24-146237 (PQ) Reviewed:11-Sep-2024, QC No. AAHBD-24-146237 Revised:16-Sep-2024,Manuscript No. AAFTP-24-146237 (R); Published:25-Sep-2024,DOI: 10.35841/2591-796X -8.4.257

Citation: Eze N. Exploring therapeutic strategies for Covid-19 management. J Food Technol Pres. 2024;8(5):257

Visit for more related articles at Journal of Food Technology and Preservation

Introduction

The COVID-19 pandemic has prompted an unprecedented global effort to develop and implement therapeutic strategies to manage and treat the disease. From early treatments to advanced therapies, the search for effective solutions has been dynamic and multi-faceted. This article explores the various therapeutic strategies employed to combat COVID-19, including antiviral drugs, monoclonal antibodies, immunomodulators, and supportive care [1].

Remdesivir is an RNA polymerase inhibitor that disrupts the replication of viral RNA. It has been authorized for emergency use in hospitalized patients with severe COVID-19. Studies have shown that it can reduce recovery time in these patients, though its impact on mortality rates remains under evaluation [2].

Paxlovid combines two antiviral agents: Nirmatrelvir, which inhibits the SARS-CoV-2 protease, and Ritonavir, which boosts Nirmatrelvir’s effectiveness. : It is used for the treatment of mild to moderate COVID-19 in individuals at high risk of developing severe disease. Clinical trials have demonstrated that Paxlovid can significantly reduce the risk of hospitalization and severe outcomes [3].

Molnupiravir introduces errors into the viral RNA, leading to defective virus replication. Molnupiravir introduces errors into the viral RNA, leading to defective virus replication [4].

This combination targets the spike protein of the virus, preventing it from entering and infecting cells. It is used to treat mild to moderate COVID-19 in high-risk patients and can reduce the risk of severe disease and hospitalization [5].

Sotrovimab binds to the spike protein of SARS-CoV-2, inhibiting its ability to bind to human cells. Approved for the treatment of mild to moderate COVID-19 in high-risk patients. It has shown efficacy in reducing viral load and symptoms [6].

These antibodies bind to the spike protein, neutralizing the virus and preventing it from infecting cells. Combination to treat mild to moderate COVID-19 in high-risk patients. Effectiveness varies with emerging variants [7].

Dexamethasone is a corticosteroid that reduces inflammation and modulates the immune response. It has been shown to decrease mortality in severe COVID-19 cases by reducing the overactive immune response associated with severe illness [8].

Continued development of vaccines, including updated versions to address new variants and improve durability of protection. Studies are underway to evaluate the efficacy of combining different therapeutic approaches, such as antivirals and monoclonal antibodies [9].

Investigating the long-term effects of COVID-19 and the potential benefits of treatments in mitigating long-term complications. Developing and adapting therapies to address new variants of SARS-CoV-2 that may affect treatment efficacy [10].

Conclusion

Exploring and implementing effective therapeutic strategies for COVID-19 is crucial in managing the pandemic and mitigating its impact. From antiviral drugs and monoclonal antibodies to immunomodulators and supportive care, a multifaceted approach is essential for treating and preventing severe outcomes. As research and clinical practice continue to advance, these therapeutic strategies will play a key role in controlling the spread of the virus, improving patient outcomes, and preparing for future public health challenges.

References

  1. Jamshaid H, et al. Diagnostic and treatment strategies for COVID-19. AAPS PharmSciTech. 2020;21:1-4.

    2. Indexed at, Google Scholar, Cross Ref

  2. Trivedi N, Verma A, Kumar D. Possible treatment and strategies for COVID-19: review and assessment. European review for medical and pharmacological sciences. 2020;24(23):12593-608.

    3. Indexed at, Google Scholar, Cross Ref

  3. Rehman SU, Rehman SU, Yoo HH. COVID-19 challenges and its therapeutics. Biomed Pharmacother. 2021;142:112015.

    4. Indexed at, Google Scholar, Cross Ref

  4. Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerg microbes & infect. 2020;9(1):687-90.

    5. Indexed at, Google Scholar, Cross Ref

  5. Liu W, et al. Strategies and advances in combating COVID-19 in China. Engineering. 2020;6(10):1076-84.

    6. Indexed at, Google Scholar, Cross Ref

  6. Siddiqi NJ, Fatima S, AlDaihan SK, Balto HA, Sharma B. Exploration of Nanotherapeutics in COVID-19. In Interaction of Coronavirus Disease 2019 with other Infectious and Systemic Diseases 2024 (pp. 164-180). CRC Press.

    7. Google Scholar

  7. Koc HC, Xiao J, Liu W, Li Y, Chen G. Long COVID and its Management. Int J Biol Sci. 2022;18(12):4768.

    8. Indexed at, Google Scholar, Cross Ref

  8. Uludag H, et al. Prospects for RNAi therapy of COVID-19. Front Bioeng biotechnol. 2020;8:916.

    9. Indexed at, Google Scholar, Cross Ref

  9. Bellera CL, et al. Can drug repurposing strategies be the solution to the COVID-19 crisis?. Expert Opinion on Drug Discovery. 2021;16(6):605-12.

    10. Indexed at, Google Scholar, Cross Ref

  10. Bajwa SJ, et al. Exploring the unknown territories in the new normal world of COVID. Journal of Anaesthesiology Clinical Pharmacology. 2020;36(Suppl 1):S77-80.

    11. Indexed at, Google Scholar, Cross Ref

Get the App